Akums Launches Enhanced Gabapentin ER Tablets with RetenEx Technology for Postherpetic Neuralgia Management
核心洞察
Akums Drugs and Pharmaceuticals (搜索) has launched an enhanced Gabapentin Extended-Release formulation incorporating proprietary RetenEx Technology for postherpetic neuralgia (搜索) management.
The DCGI (搜索)-approved tablets are available in 300 mg and 600 mg strengths, offering once-daily dosing to improve treatment adherence in elderly patients.
The formulation provides sustained drug release along targeted gastrointestinal regions, potentially reducing peak-related side effects and maintaining stable plasma levels.
Akums Drugs and Pharmaceuticals (搜索) Ltd. has announced the launch of its enhanced Gabapentin Extended-Release (ER) formulation for the management of Postherpetic Neuralgia (搜索) (PHN (搜索)), a chronic neuropathic pain (搜索) condition that often persists long after a shingles (搜索) outbreak. The new formulation incorporates the company's proprietary RetenEx Technology, designed to provide sustained drug release and enable once-daily dosing.
Clinical Need and Patient Impact
PHN (搜索) affects nearly 10 to 20 percent of patients, particularly older adults, and is associated with persistent burning pain, shooting sensations, and allodynia, significantly impairing quality of life. The condition can persist for months after a shingles (搜索) outbreak and becomes increasingly debilitating with age. Many individuals experience constant burning or throbbing discomfort, sudden shooting pain, or allodynia—symptoms that severely impact mobility, sleep, and emotional wellbeing.
While Gabapentin remains a cornerstone therapy for neuropathic pain (搜索), conventional formulations often require multiple daily dosing and may be associated with variable absorption, presenting challenges for patient adherence and optimal therapeutic outcomes.
RetenEx Technology and Formulation Benefits
Akums' new Gabapentin ER formulation incorporates the company's proprietary RetenEx Technology, engineered to enable sustained and gradual drug release along targeted regions of the gastrointestinal tract. This optimized release profile supports improved absorption, reduced peak-related side effects, and enables once-daily dosing—an important advantage for elderly patients managing multiple therapies.
The DCGI (搜索)-approved Gabapentin ER tablets are available in 300 mg and 600 mg strengths and are designed to improve treatment adherence while maintaining safety and efficacy. The extended-release profile may also help maintain stable plasma drug levels, reducing fluctuations that contribute to breakthrough pain.
Clinical Evidence and Regulatory Status
A study published on PubMed evaluating extended-release gabapentin showed that the formulation was well tolerated and demonstrated encouraging improvements on several secondary outcomes, highlighting its potential relevance in long-term PHN (搜索) management. The tablets have received DCGI (搜索) approval and are positioned as an advanced, patient-centric formulation designed to enhance treatment adherence without compromising safety or efficacy.
Company Perspective
"In chronic pain conditions like PHN (搜索), treatment sustainability and convenience are critical. With this enhanced Gabapentin ER formulation powered by RetenEx Technology, we aim to support consistent pain control through once-daily dosing, while addressing real-world adherence challenges faced by elderly patients," said Sandeep Jain, Managing Director and Founder, Akums Drugs & Pharmaceuticals Ltd.
Jain emphasized that even small improvements in convenience and daily functioning can transform a patient's quality of life. "Our focus with this enhanced Gabapentin ER formulation is to offer a solution that is not only effective but also easier to maintain for long durations, especially for elderly individuals who often manage multiple therapies," he added.
Strategic Portfolio Expansion
The launch further strengthens Akums' growing portfolio of advanced drug-delivery platforms focused on improving real-world therapeutic outcomes and patient-centric care in high-burden disease areas. By prioritizing innovation in high-burden disease areas like neuropathic pain (搜索), the company continues to advance its mission of delivering high-quality, accessible healthcare solutions across India.